HK Stock Connect Insight | ALEBUND-B (09637.HK) -26.77%; 28.25m Unlock

ALEBUND-B (09637.HK) fell 1.99% to HKD 19.700 on Nov 17 and is down 26.77% since joining Stock Connect on Sep 7; 28.25m cornerstone shares unlock on Dec 29.
Key Highlights:
  • Revenue reached RMB 104.2 million in 1H2026, up 761.2% year on year; net loss narrowed 22.5% to RMB 162.6 million.
  • The IPO was priced at HKD 22.60, with the Hong Kong public offer oversubscribed 963.56 times and 19 cornerstones taking about HKD 639 million.
  • AP301's new drug application for hyperphosphataemia was accepted by the NMPA on August 7, 2026, classified as a Class 1 chemical new drug.

ALEBUND-B edged lower on November 17, 2026, trading at HKD 19.700 as of 13:21, down 1.99%, with turnover of HKD 1.32 million and a market capitalisation of HKD 6.85 billion at the latest price. The stock touched a high of HKD 20.140 and a low of HKD 19.520 during the session, with an amplitude of 3.08%.

Over the past week, the share price moved sideways between November 10 and November 17, including today's intraday level. The stock hit an intraday high of HKD 21.600 on November 12, the peak of the period, before easing to HKD 19.700 today.

The regular adjustment of Stock Connect took effect on September 7, 2026. The number of Hang Seng Composite Index constituents rose from 534 to 580, and ALEBUND-B (09637.HK) was included and consequently admitted to Stock Connect.

ALEBUND-B listed on the Main Board of HKEX on June 29, 2026 at an offer price of HKD 22.60, offering 56.7554 million H shares and raising gross proceeds of about HKD 1.283 billion. The company listed directly on the Main Board, with the Hong Kong public offer oversubscribed 963.56 times and the international offering 19.77 times. Nineteen cornerstone investors, including GIC, Loomis Sayles, RTW and Tencent, subscribed a total of about HKD 639 million, or about 49.78% of the global offering.

On its first trading day, the stock closed at HKD 46.000, up 103.54% from the offer price, with a market capitalisation of HKD 15.63 billion. On the following trading day, June 30, it closed at HKD 45.920, down 0.17%. Within the first two trading days, the cumulative gain over the offer price remained above 100%.

Since listing on June 29, 2026, the stock has risen from the offer price of HKD 22.60 to a peak of HKD 46.820, and now stands more than 57% below that high. Since joining Stock Connect on September 7, the stock has fallen 26.77%. Its market capitalisation, which peaked at about HKD 15.63 billion shortly after listing, has fallen to HKD 6.85 billion as of November 17.

Hang Seng Indexes Company published its quarterly review results for the period ended June 30, 2026 on August 21, 2026, including ALEBUND-B in the Hang Seng Composite Index, with the change implemented after the close on September 4 and effective on September 7.

The basis for inclusion lies first in the company's addition to the Hang Seng Composite Index, which conferred the index status required for Stock Connect eligibility. Second, its market capitalisation remained within the index's coverage range around the review date. In addition, the expansion of the Hang Seng Composite Index from 534 to 580 constituents was concentrated in semiconductors, artificial intelligence and innovative drugs, a structural direction consistent with ALEBUND-B's positioning as a pure-play kidney disease drug developer.

While the inclusion provides an institutional channel for southbound participation and better liquidity, it coincides with sustained losses and a share price well below its post-listing peak.

A large lock-up expiry falls on December 29, 2026, six months after listing. The 28.2549 million H shares held by 19 cornerstone investors, equal to about 49.78% of the global offering and about HKD 639 million at the offer price, will become tradable on that date, adding pressure on the share price in the near term.

The company's core product AP301 is an oral iron-based phosphate binder for hyperphosphataemia in chronic kidney disease patients on maintenance dialysis, classified as a Class 1 chemical new drug in China, and is characterised by no need for chewing, a small swelling volume in gastric fluid and no systemic absorption. AP306, the other key pipeline asset, is the world's first and only oral pan-phosphate transporter inhibitor in clinical development and complements AP301's phosphate-binding mechanism. Its pipeline covers hyperphosphataemia, renal anaemia, IgA nephropathy and diabetic kidney disease. The company has built its own manufacturing base in Yangzhou, Jiangsu, and assembled a nephrology-focused commercial team; its commercialised product obtained exclusive sales rights in mainland China in October 2023.

Revenue has been growing, from RMB 6.53 million in 2024 and RMB 30.56 million in 2025 to RMB 104.2 million in the first half of 2026, up 761.2% year on year. Losses were RMB 335 million in 2024 and RMB 752 million in 2025, narrowing 22.5% to RMB 162.6 million in the first half of 2026. Adjusted net loss for the period fell 12.6% to RMB 130.1 million, while the gross margin rose from 43.4% to 47.3%. As of June 30, 2026, cash and cash equivalents, time deposits and wealth management products totalled RMB 1.3928 billion.

On the product and business front, ALEBUND-B made several advances in 2026: on August 7, the NMPA accepted its new drug application for AP301 in hyperphosphataemia; on July 21, the first patient was randomised and dosed in the global Phase IIb multi-regional trial of AP306; in May, the global Phase III multi-regional trial of AP301 completed enrolment of 282 patients; and in March, the company entered into a licence and equity agreement with R1 Therapeutics for AP306.

Chronic kidney disease treatment is entering a phase of accelerating adoption of innovative drugs. According to the company's prospectus, about 802 million people worldwide and about 123.8 million in China had chronic kidney disease in 2025. Public industry data indicate that the global hyperphosphataemia drug market is expected to grow from USD 1.8 billion in 2025 to USD 6.4 billion in 2035, a compound annual growth rate of about 13.3%.

Huatai Securities noted that ALEBUND is a rare Hong Kong-listed biopharmaceutical company focused on kidney disease research, with clinical data already available for its core hyperphosphataemia pipelines AP301 and AP306; AP301's new drug application has been filed in China and it is in Phase III in the United States, while AP306 has been licensed to R1 Therapeutics.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.